In samples derived from breast cancer patients, methylation of PRA, but not PRB, was predictive of lack of response to tamoxifen [47], and Wargon et al. showed in different in vivo cancer models that positive responsiveness to endocrine therapy was associated with overexpression of PRA [48]. The gene discussed is RB1; the disease is breast cancer.